IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

Lonza, Teva to Form Biosimilars JV; Lonza Starts Up Plant in China

9:56 AM MST | February 9, 2009 | DEEPTI RAMESH

Lonza and Teva Pharmaceutical Industries (Petah Tikva, Israel) say they have agreed to establish a joint venture to develop, manufacture, and market a portfolio of biosimilars. The jv is expected to start up this quarter, pending regulatory approval. Financial details of the deal were not disclosed. Yanai: Biosimilars to drive growth. The companies say they will focus on efficacious, and safe generic equivalents of certain biologic pharmaceuticals, but that they will explore other possibilities in biosimilars beyond the scope of the jv. “We had identified...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa